OSE Immunotherapeutics (OSE) investor relations material

Introduction and agenda

• KOL webcast on Tedopi and Combi-TED in NSCLC after first-line chemo-immunotherapy, scheduled for Nov. 4, 2026, at 5 p.m. CET / 11 a.m. ET; English with optional French subtitles.

• ARTEMIA is a registrational Phase 3 trial targeting 363 patients; enrollment was described as close to target.

KOL background and credentials

• Stephen Liu of MedStar Georgetown University Hospital discussed NSCLC treatment and Tedopi’s potential role.

• Federico Cappuzzo is Director of Medical Oncology at the National Cancer Institute Regina Elena and Combi-TED lead investigator.

Market insights and analysis

• U.S. lung cancer is projected to rank second in incidence in 2026 but remains the most lethal cancer; five-year survival is 28%.

• Frontline immunotherapy has transformed care, but durable benefit remains limited to a minority; docetaxel remains the second-line standard despite limited efficacy and substantial toxicity.

• Combi-TED studied HLA-A2-positive metastatic NSCLC without EGFR mutations or ALK/ROS1 rearrangements after first-line chemo-immunotherapy.

• Liu identified patients who initially respond to immunotherapy and later lose disease control as a potential group for renewed immune response.

• Therapeutic vaccines may offer an off-the-shelf option in metastatic disease, while personalized vaccines may fit the adjuvant setting.